Objective: Analysis of the diagnostic approach and management of 20 patients with hepatocellular adenoma, 1979-1996.
Setting: University Hospital Rotterdam-Dijkzigt, Rotterdam, the Netherlands.
Design: Retrospective and follow-up analysis.
Method: Medical records of patients with histologically proven hepatocellular adenoma were analysed with respect to complaints, diagnostic approach and therapeutical management. Follow-up took place at the outpatient department where history-taking, physical examination, ultrasonography and hepatitis B and C serology tests were performed.
Results: In the period 1979-1996, 20 patients with hepatocellular adenoma were treated. Eight patients (mean tumour size 3.2 cm (1.5-5)) were treated conservatively, 12 (mean tumour size 8.1 cm (6-10)) underwent hepatic resection; four because of rupture of the tumour. Serum liver enzyme values did not contribute to the diagnosis. Of the lesions 78% were diagnosed correctly by ultrasonography and 71% by computer tomography. Median follow-up of the patients treated operatively was 73 months (1-204). One patient died three years after an incomplete resection of a hepatocellular adenoma, because of a hepatocellular carcinoma. Ultrasonography did not demonstrate any recurrent tumours in the other patients. In the group of patients conservatively treated (median follow-up 39 months (24-72)) two patients died because of a hepatocellular carcinoma. Ultrasonography demonstrated stable tumour diameters in three patients and regression in three others.
Conclusion: Based on the literature and the presented experience surgical treatment is the treatment of choice in patients with large (> or = 5 cm diameter) hepatocellular adenomas because of the risk of malignant transformation and rupture of the tumour. With smaller tumours (< 5 cm) a conservative treatment may suffice in hepatitis virus negative patients, including withdrawal of oral contraceptives followed by thorough ultrasound follow-up of tumour size. In case of tumour growth or complaints a resection of the tumour is indicated.
Download full-text PDF |
Source |
---|
Sci Rep
December 2024
Department of Radiology, Seoul National University Hospital, 101 Daehangno, Jongno-gu, Seoul, 03080, Korea.
Ultrasound (US) is a widely used technique for liver disease but has limitations in distinguishing tumors. This study evaluates the clinical efficacy of fluctuational imaging (FLI), a new US method that detects the fluttering sign in liver tumors. We conducted a prospective exploratory study with 120 participants diagnosed with liver tumors through histopathology or standard imaging.
View Article and Find Full Text PDFFront Nucl Med
November 2024
Department of Radiology, Mayo Clinic, Rochester, MN, United States.
Theranostics
December 2024
Department of Nuclear Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
Distinguishing unilateral aldosterone-producing adenomas (APA) from idiopathic hyperaldosteronism (IHA), nonfunctional adrenal adenoma (NFA), and pheochromocytoma (PHEO) within primary aldosteronism (PA) presents a significant challenge. Studies have demonstrated high levels of chemokine receptor (CXCR) 4 expression in APA, thereby validating the use of Ga-labeled CXCR4 PET/CT for detecting APA. This study evaluates the efficacy of [F]AlF-NOTA-pentixather PET/CT in distinguishing APA from other PA types.
View Article and Find Full Text PDFGE Port J Gastroenterol
December 2024
Gastrenterology Department, Centro Hospitalar de Setúbal, Setúbal, Portugal.
Eur J Gastroenterol Hepatol
February 2025
Department of Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Royal Free Hospital, Royal Free London NHS Foundation Trust, London, UK.
Introduction: Our aim was to assess parameters derived from preoperative blood tests as diagnostic or prognostic markers in patients with operable hepatocellular carcinoma (HCC).
Methods: We included 210 patients who underwent liver resection as the first treatment for suspected hepatocellular adenoma (HCA) or HCC (January 2010-December 2022). Parameters originated from preoperative complete blood count and biochemical blood tests were examined for associations with clinicopathological parameters and survival.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!